Aquestive Therapeutics, Inc. (AQST)
- Zacks
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CARISMA THERAP (CARM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5Announces immediate availability of Libervant 5mg, 7.5mg, 10mg, 12.5mg, and 15mg for patients between 2 to 5 years of ageCompany track record now includes 4 FDA approvals since 2018Anaphylm program on track; NDA submission expected by the end of 2024Hosts conference call for investors on April 29 at 8:00 a.m. ET WARREN, N.J., April 29, 2024 (GLOBE NEWSWIRE)
